Sofosbuvir , ≥99% , 1190307-88-0

CAS NO.：1190307-88-0

Empirical Formula: C22H29FN3O9P

Molecular Weight: 529.45

MDL number: MFCD18782704

EINECS: 695-717-4

PRODUCT Properties

• Melting point: 122-124°C
• Density: 1.41
• storage temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• solubility: DMSO (Slightly), Methanol (Slightly)
• form: Solid
• pka: 9.39±0.10(Predicted)
• color: White
• InChIKey: TTZHDVOVKQGIBA-YBSJRAAASA-N
• SMILES: C(OC(C)C)(=O)[C@@H](N[P@@](OC[C@@H]1[C@@H](O)[C@](F)(C)[C@H](N2C(=O)NC(=O)C=C2)O1)(OC1=CC=CC=C1)=O)C
• CAS DataBase Reference: 1190307-88-0

Description and Uses

Sofosbuvir is a drug used for the treatment of hepatitis C. It is recommended to be used in combination with other drugs (such as velpatasvir) for the first-line treatment for HCV genotypes 1, 2, 3, 4, 5, and 6. It takes effect through acting as a nucleotide analog inhibitor, being capable of specially inhibiting the HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase.

PSI-7977 is a prodrug that is metabolized to the active antiviral agent 2''-deoxy-2''-α-fluoro-β-C-methyluridine-5''-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. Studies have profiled PSI-7977 as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase.

Safety

• Symbol(GHS): GHS07,GHS08
• Signal word: Warning
• Hazard statements: H373
• Precautionary statements: P260-P314-P501
• HS Code: 29339900
• Hazardous Substances Data: 1190307-88-0(Hazardous Substances Data)